Literature DB >> 1933424

Nicotinic and muscarinic interactions and choice accuracy in the radial-arm maze.

E D Levin1, J E Rose.   

Abstract

Muscarinic acetylcholine (ACh) systems have long been known to be necessary for accurate performance in cognitive tests. Nicotinic ACh systems have been shown to be involved as well. However, there is only a limited amount of information concerning the interactions of these two branches of the ACh transmitter system. The current study was conducted to investigate the improvement in choice accuracy caused by muscarinic and nicotinic agonists and how it is affected by antagonists of these systems. Adult female Sprague-Dawley strain rats (N = 11) were trained on a working memory task in an 8-arm radial maze. Acute injections of the muscarinic and nicotinic agonists, pilocarpine (PILO, 1.0 mg/kg) and nicotine (NIC, 0.2 mg/kg), were made alone or in combination with the muscarinic and nicotinic antagonists, scopolamine (SCOP, 0.1 mg/kg) and mecamylamine (MEC, 10 mg/kg). NIC administration caused a significant improvement in choice accuracy compared with saline (p less than 0.01) and PILO caused a marginally significant improvement in choice accuracy (p less than 0.06). The combination of these nicotinic and muscarinic agonists did not cause an additive improvement. However, the improvement caused by either agonist was reversed by both nicotinic or muscarinic antagonists. This reversal was more complete for NIC than PILO despite the fact that NIC caused a greater improvement than PILO. These results suggest that muscarinic and nicotinic components of the ACh system, which are both important for cognitive function, interact in important ways. These interactions may be critical to consider when devising treatments for cognitive dysfunction associated with cholinergic hypofunction such as with Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1933424     DOI: 10.1016/0361-9230(91)90293-s

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  14 in total

1.  Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses.

Authors:  Ricardo Alvarez-Jimenez; Ellen P Hart; Samantha Prins; Marieke de Kam; Joop M A van Gerven; Adam F Cohen; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

Review 2.  Nicotine and hippocampus-dependent learning: implications for addiction.

Authors:  Thomas J Gould
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

Review 3.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

Review 4.  Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Authors:  P A Newhouse; A Potter; E D Levin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

5.  Acute and chronic nicotine effects on working memory in aged rats.

Authors:  E D Levin; D Torry
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

6.  Nicotine effects in adolescence and adulthood on cognition and α₄β₂-nicotinic receptors in the neonatal ventral hippocampal lesion rat model of schizophrenia.

Authors:  Sarah A Berg; Alena M Sentir; Richard L Bell; Eric A Engleman; R Andrew Chambers
Journal:  Psychopharmacology (Berl)       Date:  2014-11-13       Impact factor: 4.530

Review 7.  Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization.

Authors:  Edward D Levin; F Joseph McClernon; Amir H Rezvani
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

8.  Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron.

Authors:  J L Muir; B J Everitt; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

9.  Nicotinic systems and cognitive function.

Authors:  E D Levin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  The role of nicotinic receptors in the amelioration of cholinesterase inhibitors in scopolamine-induced memory deficits.

Authors:  Takayoshi Masuoka; Chiaki Kamei
Journal:  Psychopharmacology (Berl)       Date:  2009-07-29       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.